Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors

Undeniably, immunotherapy has markedly improved the survival rate of cancer patients. The scenario is no different in lung cancer, where multiple treatment options are now available and the inclusion of immunotherapy yields better clinical benefits than previously used chemotherapeutic strategies. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaseq, Rohulla, Sharma, Amit, Li, Yutao, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054817/
https://www.ncbi.nlm.nih.gov/pubmed/36982701
http://dx.doi.org/10.3390/ijms24065626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054817/
https://www.ncbi.nlm.nih.gov/pubmed/36982701
http://dx.doi.org/10.3390/ijms24065626

Ejemplares similares